• main image

    Avant-Garde Therapy for Intractable Diseases

    The World’s First PEGylated Bilirubin Technology

Leadership

arrow_forward

Our Technology

arrow_forward

Patients

arrow_forward

Our Identity

Bilix is established based on the world’s first PEGylated bilirubin platform technology to produce numerous “First in Class” in anti-inflammatory and “Best in Class” in cancer therapy drugs in addition to achieving other business platform such as contrast agents for cancer diagnostics, and theranostics.

Read more

Ingenious Platform with PEGylated Bilirubin

BRIXELLE Platform is based on a proprietary technology and can be used to cure many intractable inflammatory diseases. It also can be developed into a highly potent and less toxic anti-cancer drug delivery system and other theranostics applications.

Latest news

빌릭스, 허혈성 재관류 손상 치료제 ‘브릭셀’ 호주 임상 1상 승인

On:

성인 64명 대상으로 안전성 및 내약성 평가, 연내 첫 투여임상 2상은 FDA 임상 허가 받아 미국서 2년간 진행 예정대표 “2026년 상장 목표, 기술이전으로 조기매출 낼 것” 빌릭스는 호주 인체 연구

Read More →

Top 10 Startups in Korea – 2023

On:

South Korea has emerged as a hotbed for startups in recent years due to its vibrant technological ecosystem, government support, and rapidly growing consumer base. The presence of global companies

Read More →

Bilix: Avant-Garde Therapy for Intractable Diseases

On:

Bilirubin, a compound generally found in mammals, has potent antioxidant and immune-modulatory properties. Scientists have been attempting to develop a drug using the compound but have faced challenges due to

Read More →

Collaborators

We work closely with our collaborators in all aspects of drug development and commercialization including research organizations, clinical development entities, hospitals, intellectual property experts, patient advocate groups, and governments. Our ambition is to improve patient health and care. If you are interested in collaborating with us, please contact us.